• 1. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 2. Exchanged ligands on the surface of a giant cluster: [(MoO3)176(H2O)63(CH3OH)17Hn](32 – n)–
  Chem. Commun., 1998, 1501-1502
• 3. Excited state dynamics of symmetric and asymmetric Cr3(dpa)4Cl2 measured using femtosecond transient absorption spectroscopy?
  Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477
• 4. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 5. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147

Recent Advances in the Study of 777856-62-9 and 3-(pyridin-3-yl)prop-2-yn-1-amine in Chemical Biology and Pharmaceutical Research

The compound 777856-62-9, along with its derivative 3-(pyridin-3-yl)prop-2-yn-1-amine, has recently garnered significant attention in the field of chemical biology and pharmaceutical research. These molecules have shown promising potential in various therapeutic applications, particularly in the development of novel kinase inhibitors and targeted drug delivery systems. This research brief aims to provide an overview of the latest findings related to these compounds, their mechanisms of action, and their potential clinical applications.

Recent studies have demonstrated that 777856-62-9 exhibits potent inhibitory activity against several protein kinases involved in cancer progression. Structural analysis reveals that the compound's unique molecular architecture allows for selective binding to the ATP-binding pocket of specific kinases, thereby disrupting their catalytic activity. This selectivity profile makes 777856-62-9 an attractive candidate for the development of targeted cancer therapies with reduced off-target effects compared to conventional kinase inhibitors.

The derivative 3-(pyridin-3-yl)prop-2-yn-1-amine has emerged as a valuable building block in medicinal chemistry due to its versatile reactivity and ability to serve as a linker in drug conjugates. Recent work has focused on utilizing this compound in the development of PROTACs (Proteolysis Targeting Chimeras), where it serves as a crucial component connecting the target-binding moiety to the E3 ubiquitin ligase-recruiting element. This application has shown particular promise in addressing previously "undruggable" targets in oncology and neurodegenerative diseases.

Significant progress has been made in understanding the pharmacokinetic properties of these compounds. A 2023 study published in the Journal of Medicinal Chemistry reported improved metabolic stability and oral bioavailability of 777856-62-9 analogs through strategic structural modifications. These findings address previous challenges associated with the compound's in vivo performance and pave the way for more effective clinical translation.

In the realm of drug delivery, researchers have successfully incorporated 3-(pyridin-3-yl)prop-2-yn-1-amine into nanoparticle formulations for targeted therapy. The compound's terminal alkyne group enables efficient conjugation with various payloads through click chemistry, while the pyridine moiety enhances cellular uptake. Recent in vivo studies have demonstrated enhanced tumor accumulation and reduced systemic toxicity when using these nanoparticle systems compared to conventional formulations.

Looking forward, several clinical trials are being planned to evaluate the safety and efficacy of therapies based on these compounds. The unique properties of 777856-62-9 and 3-(pyridin-3-yl)prop-2-yn-1-amine continue to inspire innovative approaches in drug discovery, with potential applications expanding beyond oncology to include inflammatory diseases and neurological disorders. As research progresses, these molecules are expected to play an increasingly important role in the development of next-generation therapeutics.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)